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It has been previously revealed that statins used at high concentrations display antileukemic potential towards chronic lymphocytic
leukemia (CLL) cells. However, their usage alone in clinical practicemay be limited due to possible side effects of high doses of these
drugs. On the other hand, combined treatment of leukemia with statins and the conventional chemotherapeutics is questionable
because of unknown influence of the first on the standard treatment results. This study has revealed that in vitro atorvastatin
increases the proapoptotic potential of cladribine and mafosfamide in CLL cells isolated from peripheral blood of patients.
Moreover, a preincubation with the above statin sensitizes leukemic cells to CM-induced apoptosis even at small concentrations of
the drug.The usage of atorvastatin together with or followed by the conventional chemotherapy should be considered as therapeutic
option for the treatment for this leukemia. Interestingly, CM-resistant patients might have the biggest benefits from atorvastatin
administration.
1. Introduction
Despite a large number of therapeutic options introduced
recently, chronic lymphocytic leukemia (CLL) remains still
an incurable disease. An increase in lymphocyte level is
caused by decreased apoptosis process and elevated sur-
vival due to both intrinsic properties of leukemic cells and
microenvironmental stimuli. The disease is highly heteroge-
neous with variable clinical course and prognosis [1]. The
new strategies for CLL treatment are still being developed
[2–4]. Currently, much attention is focused on monoclonal
antibodies, that is, rituximab and alemtuzumab, which
target CD20 and CD52 antigens, respectively. Rituximab,
cyclophosphamide, and fludarabine combination (RCF) is
thought to be the gold standard in CLL treatment [5]. How-
ever, some patients are excluded from immunotherapy since
RCF regimen augments the risk of myelosuppression [2].
Known anaphylaxis or hypersensitivity to murine proteins is
counterindications to monoclonal antibodies usage. Further-
more, rituximab administration increases significantly a risk
of development of severe infections [6]. Therefore, very high
carefulness is needed in the treatment of CLL patients with
opportunistic, recurrent, or chronic infections. In addition,
hypersensitivity pneumonitis is rare, but life-threatening
adverse effect of the antibody injection that is an indication
to rituximab discontinuation [7]. Simultaneously with the
progress in immunotherapy, improvement in conventional
chemotherapy efficiency should also take place.
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Numerous defects have been revealed in lipidmetabolism
of CLL cells. Contrary to the normal B lymphocytes, the
leukemic cells exhibit overexpression of lipoprotein lipase
(LPL), the enzyme which facilitates the hydrolysis of serum
lipoprotein triacylglycerols(triglycerides) to free fatty acids
(FFA) [8]. LPL generates ligands for peroxisome proliferator
activated receptor 𝛼 (PPAR𝛼) involved in fatty acid 𝛽-
oxidation [9]. The elevated level of this nuclear receptor has
been indicated within the quiescent CLL cells and it has been
correlated with advancement of the leukemia. The elevated
concentrations of LPL as well as PPAR𝛼 in the lymphocytes
change their metabolism towards higher utilization of FFA
[8, 9]. Moreover, it seems that in addition to its lipolytic
activity LPL must serve an extra vital function in the cells,
deregulation of which may be related to aggressive course of
the leukemia [8].
Mulas et al. [10] have demonstrated that both CLL and
ALL (acute lymphocytic leukemia) patients are characterized
by decreased serum level of high density lipoproteins (HDL),
as well as increased level of cholesterol esters within the
leukemic lymphocytes in comparison to normal ones. More-
over, the cited scientists observed the elevated level of choles-
terol esterification in the cells that had been treated with
mitogens, while its decreasing level when the neoplastic lym-
phocytes had been exposed to inhibitor of cel proliferation
such as the mTOR inhibitor, RAD. They have suggested that
cholesterol esterification might be a mode for cellular growth
control which goes via the regulation of free cholesterol
concentration in lipid rafts. Hence, the statins, drugs affecting
cholesterol biosynthesis by 3-hydroxy-3-methyl-glutharyl-
coenzyme A (HMG-CoA) reductase inhibition, could be
promising compounds targeting cholesterol-dependent path-
ways of leukemic cells’ growth and proliferation.
Although not fully understood, anticancer activity of
statins has been well documented [11–13]. It is thought to be
associatedmainlywith inhibition ofmevalonate (MVA) path-
way that is a source of molecules being of great importance
for cellular survival, that is, ubiquinone, dolichol, farnesyl
pyrophosphate (FPP), geranylgeranyl pyrophosphate (GPP),
and so forth [14–17]. These compounds determine proper
course of cellular respiration, glycoprotein assembling, or
prenylation of proteins engaged in intracellular signalization
(Rho, Ras, Rab, and Rac), respectively [18, 19]. Moreover, it
was reported that statins downregulate histone methyltrans-
ferase enhancer of zeste homolog 2 (EZH2) in colorectal
cancer cells, leading to p27KIP1 overexpression, cell cycle
arrest, and inhibition of tumor progression [20].
It has been previously revealed that statins indicate
cytotoxic potential also against CLL cells in vitro [21, 22].
Leukemic lymphocytes seem to indicate particularly high
demand for intermediate products of cholesterol biosynthesis
or cholesterol alone, which makes them more susceptible to
the blockage of HMG-CoA reductase activity than normal
ones [22].
The purpose of the current research was to compare the
proapoptotic activity of synthetic compound, atorvastatin,
with CM (cladribine + mafosfamide/cyclophosphamide)
drug combination which is conventionally used for CLL
treatment. Moreover, we aimed to establish atorvastatin
influence on the antileukemic activity of CM against primary
tumor peripheral blood mononuclear cells (PBMCs) in vitro.
2. Experimental
2.1. Patients. PBMCs were obtained from blood of 24
untreated CLL patients (18 men, 6 women) prior to the intro-
duction of the anticancer therapy.Thepatients’ characteristics
are given in Table 1.
CLL was diagnosed on the basis of standard clinical and
immunological criteria and the clinical stage.The disease was
classified according to modified Rai system [23]. Leukemic
PBMCs were characterized by the expression of CD5, CD19,
andCD23 antigens on the surface andmonoclonality for light
chains of their immunoglobulins.This study was approved by
the Local Ethics Committee of Medical University of Ło´dz´
(number RNN/143/10/KE) and all the patients gave their
written consent.
2.2. Isolation of Mononuclear Cells. PBMCs were isolated
from freshly obtained peripheral blood samples (collected
into EDTA) by Histopaque-1077 density gradient centrifuga-
tion (Sigma-Aldrich, St. Louis, MO, USA).
2.3. Fluorescence In Situ Hybridization (FISH). FISH was
performed on interphase nuclei of PBMCs obtained from
untreated CLL patients as previously described. The follow-
ing commercially available probes were used: LSI D13S319
(13q14.3)/LSI 13q34/CEP 12 probe, LSI p53 (17p13.1)/LSI ATM
(11q22.3) probe (Vysis/Abbott Molecular, USA). For each
probe, 200 interphase nuclei were scored. The estimated cut-
off levels were as follows: 8% for del(13)(q14.3), del(11)(q22.3),
del(17)(p13.1), and 5% for trisomy, respectively.
2.4. Cytometric Analysis of ZAP70 Expression. In several
cases, the assays of the intracellular expression of zeta
chain- (TCR-) associated protein kinase 70 (ZAP70) in
CD5+/CD19+ leukemic cells from previously untreated CLL
patients were made. The detection of ZAP70 was performed
according to the permeabilization and staining procedure
of Invitrogen Molecular probes. Briefly, 50𝜇L of peripheral
blood samples was incubated with FITC-conjugated anti-
CD5 and PerCP-conjugated anti-CD19 antibodies (or the
appropriate isotype controls) from Becton Dickinson for
15min in the dark at room temperature. Afterwards, 100 𝜇L
of fixation medium from Invitrogen Molecular Probes was
added to the each sample. After 15min incubation the
samples were washed in 3mL PBS + 0.1% NaN
3
+ 5% FBS
and centrifuged for 5min at 300×g. Then, the supernatant
was aspirated and 100 𝜇L of Permeabilization Medium from
Invitrogen Molecular Probes and PE-conjugated anti-ZAP70
antibody (or the corresponding isotype control) from BioLe-
gend (San Diego, CA, USA) were added. After incubation
(20min), blood cell samples were washed again in 3mL
PBS + 0.1% NaN
3
+ 5% FBS and centrifugated for 5min at
300×g. Then, supernatant was removed, whereas the cells
were resuspended in sheath fluid and immediately analyzed
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Table 1: Characteristic of CLL patients.
Sex Age Stageof CLL
Leukocytosis
[×109/L]
Chromosomal
abnormalities [analyzed
by FISH technique]
Sensitivity of PBMC to
CM [% of dead cells in
comparison to control]
Sensitivity of PBMC to 10𝜇M, 25 𝜇M, and 50 𝜇M
atorvastatin, respectively [% of dead cells in
comparison to control]
1 M 80 II 75 del 13q14 38% S 14.1% 17.5% 29.9%
2 M 51 I 46 del 11q22 54% S 12.7% 26.7% 51.9%
3 M 68 I 300 del 13q14 78.2% S 19.2% 29.7% 47.1%
4 M 77 IV 300 del 11q22, del 13q14 3.7% R 4.7% 15.2% 30.3%
5 M 53 I 64 N 67.4% S 15.4% 27.2% 46.8%
6 F 60 IV 300 ND 64.8% S 20.3% 35.1% 32.8%
7 M 56 III 224 ND 60.4% S 22.1% 25.3% 35.4%
8 M 75 III 200 N 41.8% S 20.2% 27.8% 40.3%
9 M 69 IV 300 del 13q14 10.4% R 16.6% 25.4% 41.6%
10 M 65 II 260 del 13q14 77.4% S 20.7% 28% 42%
11 F 72 III 129 del 17p13 14.7% R 9.8% 16.8% 27.8%
12 M 56 IV 136 del 13q14 64.5% S 19.5% 29.3% 49.2%
13 M 72 II 220 ND 50% S 29.7% 48.8% 71.55%
14 M 68 III 170 del 13q14 45.1% S 31% 43.9% 55.2%
15 M 59 IV 190 del 13q14 10.8% R 12% 27.1% 45.2%
16 F 65 II 180 N 30.2% S 20.7% 25% 28.5%
17 F 63 IV 150 del 13q14 2.7% R 26.2% 38.8% 46.6%
18 F 56 IV 350 N 4.4% R 34.7% 51.9% 75.3%
19 M 66 IV 600 del 13q14, del 11q22, +12 18.7% P 12.1% 27.1% 49.4%
20 M 61 I 150 +12 2.4% R 1.6% 8.8% 13%
21 F 81 I 28 ND 26.3% P 7.9% 22.9% 29.9%
22 M 80 III 30 ND 42.3% S 5.7% 7.5% 21.1%
23 M 59 0 80 del 11q22 16% P 10.5% 1.6% 10.8%
24 M 71 I 77 ND 18.6% P 11.1% 14.4% 21.8%
*Atypical CLL with only 15% of CD5+/CD19+ cells, N: normal karyotype, ND: not determined, +12: trisomy 12, del: deletion, F: female, M: male, P: PBMCs
partially sensitive to cladribine + mafosfamide drug combination, S: PBMCs sensitive to cladribine + mafosfamide, and R: PBMCs resistant to cladribine +
mafosfamide.
with FACS Canto II (Becton-Dickinson, San Jose, CA, USA)
flow cytometer.
2.5. Cell Culture and Drug Treatment. After washing of
PBMCs with phosphate-buffered saline (PBS), the cell sam-
ples (2 × 106/mL) were resuspended in RPMI 1640 medium
with 10% fetal calf serum supplemented with 2mM L-
glutamine, 100 𝜇g/mL streptomycin, and 100U/mL peni-
cillin. PBMCs were incubated for 24 and 48 h in standard
conditions, that is, at 37∘C in an atmosphere of 5% CO
2
.
The model cells were exposed to atorvastatin at 10 𝜇M,
25 𝜇M, and 50 𝜇M, combinations of cladribine and mafos-
famide (an active form of cyclophosphamide), as well as
cladribine, mafosfamide, and atorvastatin. The cell samples
without drug(s) or with DMSO (solvent for atorvastatin)
were considered as controls (Ctr) and vehicle controls,
respectively. Cladribine and mafosfamide were added to
culture medium at concentrations which corresponded to
their concentrations in serum of CLL patients during CC
(cladribine + cyclophosphamide) chemotherapy: 0.175 𝜇M
and 2.5 𝜇M, respectively.
Atorvastatin was purchased from LKT Laboratories Inc.
Cladribine was obtained from the Institute of Biotechnology
and Antibiotics, Bioton (Warsaw, Poland), whereas mafos-
famide was from Baxter Oncology GmbH (Frankfurt, Ger-
many).
Moreover, to evaluate whether a pretreatment of CLL cell
probeswith smaller doses of atorvastatin has an impact on the
cell susceptibility to conventional chemotherapeutic agents,
that is, cladribine and mafosfamide, PBMCs were incubated
with 0.1𝜇M and 1 𝜇M of atorvastatin for 24 h. Then, the
culture medium was changed and the cells were exposed to
CM for next 48 h.
2.6. Cell Viability and Apoptosis/Necrosis Rate. To evalu-
ate the viability of leukemic PBMCs, as well as the per-
cent of apoptotic and necrotic cells in the populations of
PBMCs exposed to the tested agents Membrane Perme-
ability/Dead Cell Apoptosis Kit from Invitrogen Molecular
Probes (Eugene, OR) was used according to the manufac-
turer’s protocol. The mononuclear cell population was gated
on the basis of FSC (forward scatter) and SSC (side scatter)
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parameters. The analyses were made after 24 and 48 h cell
exposure to the investigated drugs and quantified using LSR
II cytometer (Becton-Dickinson, San Jose, CA, USA).
In 4 experiments cell viability and apoptosis rate were
evaluated after the preincubation with atorvastatin, as well as
after 24 and 48 h exposure to CM.The results were compared
with those obtained for a coincubation of PBMCs from the
same patients with atorvastatin in combination with CM for
48 h.
2.7. Caspase-3 Activation. To assess the percent of PBMCs
with active form of caspase-3 in control and drug-treated cell
population PE active caspase-3 apoptosis kit (BD Pharmin-
gen, San Diego, CA) was used. The analyses were performed
after 48 h of incubation with the tested agents according
to manufacturer’s protocol. The measurements were made
by LSR II flow cytometer (Becton-Dickinson, San Jose, CA,
USA).
2.8. DNA Content. DNA content in PBMC samples was
estimated after 24 and 48 h incubation with/without tested
drugs as it was previously described [22]. Briefly, 1 × 106
cells were fixed with 70% ethanol and incubated at −20∘C for
2 h. Subsequently, the cells were incubated in the presence
of RNAse A (at final concentration in PBS of 0.5mg/mL)
and propidium iodide (PI; at final concentration in PBS
of 0.01mg/mL) for 30min, at 37∘C in the dark. Then, the
fluorescence of PI was measured by flow cytometry (FACS
Canto II; Becton-Dickinson, San Jose, CA, USA) and the
number of sub-G1 cells was estimated on the basis of FL-
3 histograms using FACS Diva Software (Becton-Dickinson,
San Jose, CA, USA). Ten thousand events were examined for
each analysis.
2.9. Protein Separation and Immunoblotting. Leukemic
PBMCs were lysed and prepared for Western blot analysis as
it was previously described [24]. A protein quantitation in
the cell lysates was performed according to Lowry method
[25]. About 50𝜇g of proteins was loaded per each lane
and the probes were separated by SDS-PAGE into 8% and
12.5% slab gels, depending on the molecular weights of
the analyzed proteins, respectively [26]. Then, the proteins
were transferred onto immobilon P according to Towbin
et al. [27] and stained reversibly with 0.05% Ponceau S
solution to confirm their equal loading. Subsequently,
the membranes were incubated in the presence of 5%
nonfat dry milk in TBST buffer (10mM Tris-HCl (pH
7.5), 150mM NaCl, and 0.05% Tween 20) for 1 h at room
temperature with successive incubation overnight with
specific antibodies in the following dilutions: anti-PARP-1
(1 : 5000; sc-7150), anti-lamin B (1 : 2000; sc-6216), anti-
caspase-9 (1 : 5000; sc-8355), anti-Mcl-1 (1 : 5000; sc-819),
anti-Bcl-2 (1 : 1000; sc-492), and anti-Bax (1 : 1000; sc-
1035), all from Santa Cruz Biotechnology (Santa Cruz,
CA), anti-caspase-3 (1 : 1000) from Sigma-Aldrich, anti-
ZAP70 (1 : 1000) from Cell Signaling, as well as anti-actin
(1 : 1000) antibody from Abcam (Cambridge, UK). After
being washed 3 times in TBST buffer, the membranes
were incubated with secondary antiserum conjugated with
alkaline phosphatase (Sigma-Aldrich) for 2 h and washed 3
times again.The antigen-antibody complexes were visualized
after incubation of membranes with a phosphatase substrate
solution containing: 0.33mg/mL of nitro blue tetrazolium,
0.17mg/mL of 5-bromo-4-chloro-3-indolyl phosphate in
100mM Tris-HCl (pH 9.5), 100mMNaCl, and 5mMMgCl
2
.
In some experiments, secondary antibodies conjugated with
horse radish peroxidase were applied. Then, Novex HRP
chromogenic substrate (TMB) from Invitrogen was applied
for detection of proteins.
2.10. Statistical Analysis. All results are presented as themean
value ± S.D. The statistical data analysis was performed by
Anova with Tukey’s post hoc test. The data obtained for
atorvastatin and the combinations of atorvastatin with CM
were compared with the results from DMSO treated cells
(vehicle control), whereas CM combination effectiveness was
compared with the model cells incubated without drugs
(Ctr). The results were considered statistically significant at
𝑝 ≤ 0.05.
Moreover, the Wilcoxon signed rank test was used to
statistically evaluate the differences in cytotoxicity of the
tested drugs in CM-sensitive and CM-resistant groups of
PBMC samples.
3. Results and Discussion
3.1. FISH Analysis. In the current study, 4 of 18 analyzed
CLL patients indicated normal FISH results (see Table 1).The
most common chromosomal abnormality detected among
the examined group of CLL patients was deletion of 13q14
(8 patients), which is generally observed in ∼70% of patients
with CLL and is associated with good prognosis as a sole
abnormality [2]. Deletions of 17p13 and 11q22-q23 were found
in 1 and 2CLL patients enrolled in FISH analysis, respectively.
These chromosomal aberrations are both connected with loss
of function of TP53 tumor suppressor gene as well as the
resistance to purine analogs and are related to worst (ATM)
and the worst (TP53) prognosis [1, 4, 5]. Two CLL patients
were characterized by deletions of 11q22 together with 13q14
and deletion of 11q22 associatedwith del 13q14 and trisomy 12,
respectively. Trisomy 12 as a sole abnormality was observed in
one patient only.
In the current study the proapoptotic potential of ator-
vastatin alone, as well as in combination with CM, was not
related to the presence of high risk prognostic markers, such
as del 17p13 or del 11q22-23.
3.2. Cell Viability and Apoptosis/Necrosis Evaluation. To
verify whether the drugs frequently prescribed for elder
people in connection with the hypercholesterolemia could
be profitable or inversely unfavourable for the cured CLL
patients who are usually over 60 years old we tested both
higher and lower concentrations of atorvastatin with regard
to its putative proapoptotic potential against CLL cells.
The viability of PBMCs obtained from blood of 24 CLL
patients enrolled in the study was essentially decreased by
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(d) Apoptosis induction on the basis of caspase-3 activation in PBMCs from exemplary patient number 13
Figure 1: Antileukemic potential of atorvastatin (A), cladribine + mafosfamide combination (CM), or atorvastatin in combination with
cladribine + mafosfamide (CM + A) evaluated on the basis of cell viability (a) and apoptosis induction (b–d) examination after 24 and 48 h
CLL cell exposure. Proapoptotic activity of the tested drugs was evaluated by Permeable/Dead Cell Apoptosis Kit (b), DNA content analysis
(c), and PE active caspase-3 apoptosis kit (d). ∗the results were statistically significant at 𝑝 ≤ 0.05.
atorvastatin used alone (A), as well as atorvastatin in combi-
nation with cladribine and mafosfamide (CM), that is, CM +
A.The assays of early apoptotic cell number in population of
the examined probes exposed to the used agents confirmed
proapoptotic potential of atorvastatin, as well as the con-
ventional applied combination, CM.The average cytotoxicity
and proapoptotic activity of the tested drugs are presented
in Figures 1(a) and 1(b). A combination of purine analog
and the alkylator exhibits strong proapoptotic potential,
especially after 48 h. Cell exposure to CM 24 h was less
efficient than 24 h exposure to 25 𝜇Mand 50 𝜇Matorvastatin.
After 48 h, however, the impact of 25 𝜇M compound was
comparable to the action of CMcombination. Although there
was not establishedmaximal dose of statin that could be used
in human without inducing potent cytotoxicity, this drug
concentration might be unattainable for anticancer therapy.
Therefore, we evaluated the potential of CM+A combination
to induce apoptosis in CLL cells. A combined treatment of
CM and 10 𝜇M atorvastatin (CMA10) was more effective
than CM. The improvement in antileukemic potential of
tested drugs in comparison to CM alone was about 10%
as assessed by Membrane Permeability/Dead Cell Apoptosis
kit. The 48 h incubation of the model cell samples with CM
used in combination with 50𝜇M atorvastatin was associated
with widespread late apoptosis/secondary necrosis of PBMCs
(Figure 1).
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The cell samples were divided on the basis of their
sensitivity towards the conventional chemotherapeutic com-
binations in vitro. We classified them into one of three groups
(compare Table 1): the first one: CM-sensitive (S), the second
one: partially sensitive (P), and the third one: CM-resistant
(R), when CLL cell exposure to CM decreased cell viability
over 30%, 15%–30%, and less than 15% after 48 h, respectively.
As it is illustrated in Table 1 among examined 24 CLL cell
samples the biggest group (13; 54%) responded to CM, but
7 cases (29%) did very weakly. Four cases (17%) indicated
partial response to CM.
When we compared the average cytotoxicity of atorvas-
tatin, CM, and their combination in CM-resistant PBMCs in
vitro the used statin, even at the lowest concentration, caused
higher antileukemic potential than CM drug combination
(shown in Figure 2-R). In all of leukemic cell samples which
were classified as CM resistant, 25 𝜇M atorvastatin decreased
the cell viability with higher efficiency than CM. Moreover,
a combination of atorvastatin and CM caused potentiated
cytotoxic effect in leukemic PBMCs in comparison to CM.
In 6 of 7 CM-resistant cell samples atorvastatin at 10 𝜇M
triggered apoptosis of PBMCs at higher degree than the CM
after 48 h. Differences in the cytotoxicity induced by CM +
A25 and CM + A50 versus CMwere statistically significant at
𝑝 < 0.05 and 𝑝 < 0.02, respectively (Wilcoxon signed rank
test). The average decrease in the viability of CMA10-treated
cells was ∼20% in comparison to the cell samples exposed to
CM.
Fromamong all the tested cell samples, only the examined
probes obtained from blood of the patient number 20 were
not susceptible to both CM and atorvastatin. In the rest
of investigated CLL samples the resistance to conventional
anticancer drug combination – CM did not go together with
their resistance towards atorvastatin which is related to their
different mechanisms of action against the model cells.
As it is illustrated in Figure 2-P, in CLL cell group
classified as partially sensitive to CM, 50 𝜇M atorvastatin
displayed the most antileukemic potential from among all
tested atorvastatin doses, similarly as CM combination, while
CM + A10 combination induced ∼10% decrease in the cell
viability in comparison to CM. The effect caused by these
drugs was additive.
In contrast, in CM-susceptible CLL cell group the CM
combination operatedmore efficiently than atorvastatin used
at all tested concentrations (compare Figure 2-S). Ator-
vastatin also indicated cytotoxic potential higher than that
observed in CM-resistant CLL cells. Although combined
action of atorvastatin and CM showed infra-additive effect
on the leukemic PBMCs, the increase in antileukemic activity
of examined agents was statistically significant (𝑝 < 0.01
for CM and CM + A10 pair of samples and 𝑝 < 0.002
for higher statin concentrations; Wilcoxon signed rank test).
On average, adding 10 𝜇M atorvastatin to CM triggered only
about 5% decrease in examined cell viability in comparison
to conventional CM combination.
Meanwhile, as it is shown in Figure 3, the preincubation of
CLL cell samples with atorvastatin, even at 1 𝜇M, diminished
their viability in comparison to the cells treated only with CM
(without the previous preincubation).
3.3. DNA Content. DNA content assays were performed in
cell samples from blood of 13 CLL patients. The average
results of DNA content analysis in PBMCs exposed to the
examined drugs are presented in Figure 1(c). Sub-G1 cell
population of PBMCs corresponding to the population with
apoptotic DNA fragmentation enlarged after 24 and 48 h
incubation with all the tested agents in comparison to control
(and the cells exposed to DMSO, solvent for atorvastatin).
There was no difference between the DNA content in con-
trol cells and the vehicle control. The CM combination
induced 4- and 3-fold increase in sub-G1 cell number in
comparison to control PBMCs after 24 and 48 h, respectively.
Apoptosis confirmed by the presence of sub-G1 cells rises
in statin-treated PBMCs in dose-dependent manner. The
lowest concentration of atorvastatin triggered 2-fold raise
of subdiploid PBMC population in comparison to control
with DMSO. Atorvastatin used solely at the concentration
of 50𝜇M induced the changes in DNA content of the cells
higher than those observed in PBMC samples incubated with
CM(∼50% versus 43%). Importantly, the combined treatment
of the model cells with 10 𝜇M atorvastatin and CM was
more effective (∼15% and more) than CM alone. The adding
of atorvastatin at higher concentrations than 10 𝜇M to CM
combination increased antileukemic potential of the latter.
In some cases, however, extreme DNA nucleolysis made
impossible to reliably analyze the DNA content of the cells
(these cases were excluded from analysis).
3.4. Caspase-3 Activation. Thepercentage of PBMCs express-
ing the active form of caspase-3 was assessed cytometri-
cally. The obtained results confirm proapoptotic potential of
used concentration of atorvastatin, CM, as well as CM in
combination with atorvastatin. In the model cells, apoptosis
induction intensified proportionally to the dose of inves-
tigated agents, gaining over 45% increase in CM-treated
cells in comparison to control and over 40% and 65% in
PBMCs exposed to atorvastatin at concentrations of 25𝜇M
and 50 𝜇M, respectively (exemplary patient number 13; see
Figure 1(d)). The mean proapoptotic potential of CM was
higher than that of 25 𝜇M atorvastatin but lower than that
of statin at 50𝜇M. Low increase in apoptotic cell number
in vehicle control in comparison to the cells without DMSO
was noted. Importantly, the treatment of leukemic cell probes
with atorvastatin and CM together was more efficient than
these drugs used separately.
3.5. Immunoblotting Assay. To evaluate the proapoptotic
potential of atorvastatin in drug-treatedCLL cells, the expres-
sion levels of chosen apoptosis markers, that is, poly(ADP-
ribose) polymerase-1 (PARP-1) and lamin B1, were examined.
Both of these nuclear proteins are proteolytically cleaved
by active caspases in the execution phase of apoptosis [28,
29]. The obtained results confirmed the cleavage of these
apoptotic markers followed by the cell exposure to CM com-
bination, as well as to atorvastatin alone or to its combination
with CM. In 5 cases, 48 h exposure to CM did not induce the
changes in the expression level of the full length proteins with
a mass of 116 kDa and 67 kDa, respectively. However, after
Journal of Chemistry 7
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the incubation of CLL cells with atorvastatin at rising concen-
tration, the proteolysis of PARP-1 and lamin B1 was observed
in 4 of them. Concomitantly, the elevated cleavage products
of 85 kDa and 44 kDa, respectively, were seen. Hence, a slight
susceptibility of leukemic cells to cladribine andmafosfamide
does not have to be related to their resistance to the statin.
The investigation of procaspase-9 and procaspase-3
expression by Western blot revealed that the used com-
pounds influenced cellular level of the zymogens which
was presumably caused by the activation of these enzymes
(see Figure 2). The obtained data suggest an involvement
of mitochondria in apoptosis course in CLL cells exposed
to the tested agents. Similarly, Cafforio et al. [30] have
previously indicated mitochondria as the organelles involved
in statin-induced apoptosis.We postulate, however, that these
organelles are not central for initiation of apoptosis in statin-
treated CLL cells. The mitochondrial pathway of apoptosis
in statin-treated cells was not firmly confirmed by Bcl-2 (B-
cell leukemia/lymphoma 2) family protein expression data.
Although the dropping of Mcl-1 (myeloid cell leukemia 1;
∼40 kDa) cellular level was seen inmost cases ofCLL samples,
as it is shown in Figure 2, this change was not accompa-
nied by the spectacular diversities in the expression level
of antiapoptotic–Bcl-2 and proapoptotic–Bax (Bcl-2 associ-
ated × protein) proteins. The increased Bax expression was
observed inCM-sensitiveCLL cell probes after their exposure
to the conventional CM combination or its application with
atorvastatin (see Figure 2-S). Additionally, a comparison of
these protein expression levels revealed that the proteolysis
of apoptosis-related proteins, PARP-1 and lamin B1, was
observed together with the putative activation of caspase-9
and caspase-3, and it sometimes proceded the Mcl-1 level
decline (see Figure 2-S; patient number 1 and Figure 2-P;
patient number 19). Therefore, it suggests that the alterations
in Mcl-1 expression could be associated with its proteolysis
during apoptosis, not the reason of apoptosis induction.
Importantly, the Bcl-2 expression decline was only seen after
the cell exposure to the highest drug concentrations.
Furthermore, the expression of ZAP70 kinase was esti-
mated in several CLL cell samples incubatedwith atorvastatin
alone, CM, and CM with atorvastatin. A high intracellular
expression of this enzyme is thought to be a negative prognos-
tic factor for CLL [2]. Of note, Western blot assay indicated
that in vitro exposure to atorvastatin resulted inZAP70 kinase
decrease in PBMCs from blood of ZAP70-positive patients
(the positivity was confirmed by flow cytometry) that is
in agreement with the results of Yavasoglu et al. [31]. The
observed ZAP70 protein level decline is likely to be associated
with executive phase of apoptosis, since analogous effect was
also detected in CM-susceptible leukemic cells obtained from
blood of exemplary patient number 1 exposed in vitro to CM.
Moreover, no correlation between ZAP70 expression and the
susceptibility of PBMC samples to the tested drug(s) was
noticed.
The causal involvement of apoptosis disturbances and
chromosomal aberrations and the evaluation of leukemic
cell responses to drugs/experimental compounds have been
demonstrated in leukemia cell lines [32, 33], primary CLL
cell samples [33–36], and animal models [37, 38]. Recently,
reported data presented in vivo mouse models [38, 39] to
explain how different components of the microenvironment
contribute to this hematological neoplasm pathogenesis. An
interesting approach involving the usage of CLL cells/nurse-
like cells coculturemodel for the investigation leukemia cells-
microenvironment interactions after drug treatment was
described [40]. The in vitro testing of CLL cells exposed
to drug(s) was applied in Differential Staining Cytotoxicity
test, DiSC [34], which recently was improved and simplies
as TRAC (tumor response to antineoplastic compounds) [35,
41].
Summarizing, our results reveal that atorvastatin essen-
tially increases the proapoptotic potential of drug combina-
tion, CM inCLL cells in vitro. In addition, even small doses of
atorvastatin applied during the preincubationmight intensify
the cytotoxicity of CM against the leukemic cells in vitro.
It seems, therefore, that atorvastatin usage by CLL patients
during or before anticancer therapy is not a counterindication
to cladribine and cyclophosphamide application. Conversely,
it might intensify the efficacy of conventional chemother-
apy. Supportive effect of atorvastatin and CM combination
may be associated with their distinct modes of action. The
conventional anticancer agents trigger cell death mainly by
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generating injuries within DNA and RNA molecules leading
to apoptosis on mitochondrial pathway [42]. The metabolic
changes provoked by statins in leukemic cells might induce
cell death regardless of the changes in the Bcl-2 family protein
expression and caspase-9 activation. It may be associated
with endoplasmic reticulum (ER) stress-dependent apopto-
sis, which is a major mechanism involved in spontaneous
apoptosis of CLL cells, or autophagy [43–45]. In addition
to proapoptotic potential, atorvastatin might also affect the
efflux of anticancer agents outside the cells, similarly as lovas-
tatin which has been shown to inhibit the activity of (ATP)
binding casette drug transporters in leukemic cells [46].
It has been previously suggested that statins should not
be administered to the patients cured with immunotherapy
[47]. The combined treatment of statins and monoclonal
antibodies was unadvisable due to possible influence of these
drugs on cellular localization and structure of leukemic cell
antigens. Very recently published data suggest, however, that
statins marginally affect rituximab-dependent ADCC (anti-
body dependent cellular cytotoxicity) [48]. Interestingly, it
has been recently established that cholesterol moleculesmask
tumor-associated membrane glycosphingolipids enabling
tumor escape from immune system recognition. Hence,
statins could facilitate immunosurveillance by the reduction
of cholesterol level in the membranes of some types of cancer
[49, 50]. In light of these data it seems possible that the bene-
fits of statin cotreatmentmight be higher than their disadvan-
tages also for the patients treated with immunotherapy. Some
of lately published results indicating improved response rate
and survival among the patients with relapsed or refractory
CLL who received statins and/or aspirin together with RCF
have supported above notion [51]. Similarly, Lee et al. have
[52] revealed that statins are able to potentiate the antiangio-
genic effects of bevacizumab in colorectal cancer cells. On
the other hand, there are a lot of controversies associated
with statin usage [50, 53]. High dose of atorvastatin used
during anticancer therapy might result in drug induced liver
injury (DILI) in susceptible patients [54]. Another possibility
is enhanced risk of diabetes development, especially among
elder patients.The diabetogenic potential of statins occurring
after about 4-year treatment with statins was reported [55].
4. Conclusions
The obtained results indicate that in vitro atorvastatin alone
is able to induce apoptosis in CM-sensitive and CM-resistant
chronic lymphocytic leukemia cells. Moreover, coincubation
or preincubation with atorvastatin sensitizes CLL cells to
CM-induced apoptosis and should be considered as thera-
peutic option for CLL patients. It seems that the patients
who are CM-resistant and/or these oneswith poor prognostic
markers for the treatment with conventional chemotherapy
might have bigger benefits from atorvastatin introduction.
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